ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
102.36
+0.35 (+0.34%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close102.01
Open102.15
Bid101.10 x 800
Ask102.34 x 1100
Day's Range101.25 - 102.93
52 Week Range34.53 - 114.20
Volume471,317
Avg. Volume416,995
Market Cap3.939B
Beta (3Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-6.10
Earnings DateFeb 19, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est107.37
Trade prices are not sourced from all markets
  • GlobeNewswire

    Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing

    Spark Therapeutics (ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has teamed up with Danelle Umstead – three-time Paralympian and bronze medalist, 53-time world cup medalist, “Dancing with the Stars” contestant, wife and mom who was clinically diagnosed with retinitis pigmentosa (RP), an inherited retinal disease (IRD) eventually leading to complete blindness – to encourage people living with IRDs to pursue genetic testing to uncover the genetic cause of their condition. Danelle is sharing her personal journey and genetic testing experience as part of Eye Want 2 Know®, an initiative aimed at helping people living with IRDs gain more information about their disease through genetic testing.

  • Philadelphia Immuno-oncology company Imvax hires CEO
    American City Business Journals

    Philadelphia Immuno-oncology company Imvax hires CEO

    Imvax Inc., a Philadelphia immunotherapy company focused on developing a new way to treat brain cancer, has hired former Spark Therapeutics executive John P. Furey to serve as its first full-time CEO. Furey was the chief operating officer at Spark, a gene therapy pioneer spun out of Children’s Hospital of Philadelphia (CHOP), for two years before leaving in January. Earlier in his career, he spent 15 years at Pfizer, where he last served as general manager for the company’s vaccine unit.

  • ETFs Poised to Benefit from Gene Editing Revolution
    Zacks

    ETFs Poised to Benefit from Gene Editing Revolution

    Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

  • Reuters

    UPDATE 1-Roche CEO touts drugs pipeline, rules out M&A just to boost sales

    Swiss drugmaker Roche sees medicines in its own pipeline driving sales growth over the longer term, Chief Executive Severin Schwan told Reuters on Friday, adding he will not pursue takeovers simply to keep revenue rising. In an interview at Roche's Basel headquarters, Schwan also said ongoing U.S. Federal Trade Commission (FTC) scrutiny of Roche's $4.3 billion takeover of Spark Therapeutics came as a surprise, forcing delays. Roche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for multiple sclerosis and Hemlibra for haemophilia A offset incursions by rivals' copies of its $22 billion-per-year cancer trio Herceptin, Rituxan and Avastin.

  • Roche CEO touts drugs pipeline, rules out M&A just to boost sales
    Reuters

    Roche CEO touts drugs pipeline, rules out M&A just to boost sales

    Swiss drugmaker Roche sees medicines in its own pipeline driving sales growth over the longer term, Chief Executive Severin Schwan told Reuters on Friday, adding he will not pursue takeovers simply to keep revenue rising. In an interview at Roche's Basel headquarters, Schwan also said ongoing U.S. Federal Trade Commission (FTC) scrutiny of Roche's $4.3 billion takeover of Spark Therapeutics came as a surprise, forcing delays. Roche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for multiple sclerosis and Hemlibra for haemophilia A offset incursions by rivals' copies of its $22 billion-per-year cancer trio Herceptin, Rituxan and Avastin.

  • Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded
    Yahoo Finance

    Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded

    Roche, Spark, AstraZeneca, Snap, Walmart and eBay are the companies to watch

  • $4.3B deal delayed again: Roche extends Spark Therapeutics offer for sixth time
    American City Business Journals

    $4.3B deal delayed again: Roche extends Spark Therapeutics offer for sixth time

    The slow-moving regulatory review process is once again being blamed for the latest delay in Roche’s proposed $4.3 billion acquisition of Philadelphia gene therapy pioneer Spark Therapeutics Inc. Roche said on Monday it is extending the offering period of its previously announced $114.5 per share tender offer to purchase all of the outstanding shares of common stock of Spark (NASDAQ: ONCE) to Oct. 1. The move marks the sixth time the tender offer deadline was extended since the deal was announced in late February.

  • Roche, Spark again extend $4.3 billion takeover offer
    Reuters

    Roche, Spark again extend $4.3 billion takeover offer

    Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue. The offer for Spark shares now runs to Oct. 1, Roche said. Around 24.1% of Spark's outstanding shares had been tendered as of the end of August.

  • GlobeNewswire

    Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

    PHILADELPHIA, Aug. 27, 2019 -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic.

  • Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.
    American City Business Journals

    Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.

    The proposed sale of the Philadelphia gene therapy pioneer continues to be delayed by ongoing regulatory reviews by the FTC and CMA.

  • Benzinga

    The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...

  • Analysts Estimate Spark Therapeutics (ONCE) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Spark Therapeutics (ONCE) to Report a Decline in Earnings: What to Look Out for

    Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised
    Zacks

    Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

    Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

  • The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On
    Motley Fool

    The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On

    Gene therapy developers might steal all of the headlines, but manufacturing is likely to be the more lucrative investing opportunity -- for both companies and investors.

  • Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
    Zacks

    Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)

    Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.

  • Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
    Zacks

    Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline

    Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.

  • BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
    Zacks

    BioMarin (BMRN) to File for Hemophilia A Candidate in Q4

    BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.

  • Spark, Roche extend deadline for completing $4.3 billion merger into early 2020
    American City Business Journals

    Spark, Roche extend deadline for completing $4.3 billion merger into early 2020

    The deadline was extended to provide more time to deal with antitrust regulators in the United States and the United Kingdom, who must approve the proposed Roche-Spark merger.

  • Reuters

    Roche, Spark push back takeover deadline in $4.3 billion deal

    Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year. The new deadline for both companies to extend the merger agreement is now April 30, 2020, rather than Jan. 31, 2020, Roche said in a U.S. regulatory filing on Monday, saying the change provides "additional time to clear the transaction". Roche's March 5 bid to add Spark's gene therapy technology is dragging on, with completion pushed back several times as the Swiss company blames time-consuming U.S. Federal Trade Commission scrutiny of any competition issues.

  • Reuters

    UPDATE 1-Roche, Spark push back takeover deadline in $4.3 bln deal

    Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year. The new deadline for both companies to extend the merger agreement is now April 30, 2020, rather than Jan. 31, 2020, Roche said in a U.S. regulatory filing on Monday, saying the change provides "additional time to clear the transaction". Roche's March 5 bid to add Spark's gene therapy technology is dragging on, with completion pushed back several times as the Swiss company blames time-consuming U.S. Federal Trade Commission scrutiny of any competition issues.

  • Despite Recent Volatility, Biotech Stocks Look Poised to Pop
    Investopedia

    Despite Recent Volatility, Biotech Stocks Look Poised to Pop

    Recent news from a leading gene therapy company highlights the risks, but the charts suggest ample room to the upside for biotech stocks.